BellPotter Marketing

Avita Medical (AVH) announced that the Centre for Medicare/Medicaid (CMS) has approved a new reimbursement code that will provide separate payment for Recell devices used in the outpatient setting.

The price target is lowered by 4% to $26.00 (previously $27.10). Given a 12-month TSR of less than 15%, we maintain a Hold rating for WBC.

ERD released a mixed 2Q22 trading update, with impressive unit growth in NZ and Australia, overshadowed by a disappointing result in the US.

NAB will report its FY21 result on Tuesday 9 November and we elaborate our on our forecasts

DOC is expected to report 3Q21 revenues and cash flows next week.

We initiate coverage on Coventry Group (CYG), a multi-disciplinary industrial supply and services group, with a Buy recommendation and PT of $1.90ps